Literature DB >> 30090948

Interferon gamma decreases intestinal epithelial aquaporin 3 expression through downregulation of constitutive transcription.

Michael A Peplowski1, Michael Dicay1, Cristiane H Baggio1, Filip Wysokinski1, Bernard Renaux1, Morley D Hollenberg1,2, David Proud1, Wallace K MacNaughton3,4.   

Abstract

Aquaporin (AQP) 3 expression is altered in inflammatory bowel diseases, although the exact mechanisms regulating AQP abundance are unclear. Although interferon gamma (IFNγ) is centrally involved in intestinal inflammation, the effect of this cytokine on AQP3 expression remains unknown. HT-29 human colonic epithelial cells were treated with IFNγ to assess AQP3 mRNA expression by real-time RT-PCR and functional protein expression through the uptake of radiolabelled glycerol. Transient knockdown of signal transducer and activator of transcription 1 (STAT1), STAT3, Sp1, and Sp3 were performed to determine the involvement of these transcription factors in the IFNγ-induced signalling cascade. AQP3 promoter regions involved in the response to IFNγ were assessed using a luciferase reporter system. Likewise, enteroids derived from human colonic biopsies were also treated with IFNγ to assess for changes in AQP3 mRNA expression. IFNγ decreased AQP3 mRNA expression in HT-29 cells in a time- and concentration-dependent manner and reduced functional AQP3 protein expression (decreased 3H-labelled glycerol uptake). IFNγ also reduced AQP3 expression in enteroids derived from human colonic biopsies. Knockdown of STAT1 partially prevented the IFNγ-induced downregulation of AQP3 expression, whereas STAT3 and Sp3 knockdowns resulted in increased baseline expression of AQP3 but did not alter IFNγ-induced downregulation. Constitutive transcription of AQP3 is downregulated by IFNγ as demonstrated using the luciferase reporter system, with Sp3 bound to the AQP3 promoter as shown by chromatin immunoprecipitation. AQP3 constitutive transcription in intestinal epithelial cells is downregulated by IFNγ. This response requires STAT1 that is postulated to drive the downregulation of AQP3 expression through increased acetylation or decreased deacetylation the AQP3 promoter, ultimately resulting in decreased constitutive transcription of AQP3. KEY MESSAGES: • IFNγ suppresses the expression of AQP3 in intestinal epithelial cells. • Proximal AQP3 promoter elements are sufficient to drive constitutive expression and mediate the IFNγ-induced downregulation of AQP3 mRNA expression. • IFNγ-induced suppression of AQP3 is dependent upon STAT1 expression, but not STAT3, Sp1, or Sp3.

Entities:  

Keywords:  Inflammatory bowel disease; Signal transducer and activator of transcription (STAT); Transcriptional repression

Mesh:

Substances:

Year:  2018        PMID: 30090948     DOI: 10.1007/s00109-018-1681-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  45 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  24-hour rhythm of aquaporin-3 function in the epidermis is regulated by molecular clocks.

Authors:  Naoya Matsunaga; Kazufumi Itcho; Kengo Hamamura; Eriko Ikeda; Hisako Ikeyama; Yoko Furuichi; Miyako Watanabe; Satoru Koyanagi; Shigehiro Ohdo
Journal:  J Invest Dermatol       Date:  2014-01-13       Impact factor: 8.551

3.  Inhibition of Na+,K+-ATPase by interferon gamma down-regulates intestinal epithelial transport and barrier function.

Authors:  K Sugi; M W Musch; M Field; E B Chang
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

4.  Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process.

Authors:  Matthias Bruewer; Markus Utech; Andrei I Ivanov; Ann M Hopkins; Charles A Parkos; Asma Nusrat
Journal:  FASEB J       Date:  2005-06       Impact factor: 5.191

Review 5.  Integrative immunophysiology in the intestinal mucosa.

Authors:  M H Perdue; D M McKay
Journal:  Am J Physiol       Date:  1994-08

6.  Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice.

Authors:  R Ito; M Shin-Ya; T Kishida; A Urano; R Takada; J Sakagami; J Imanishi; M Kita; Y Ueda; Y Iwakura; K Kataoka; T Okanoue; O Mazda
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

7.  Aquaporin 3 and 8 are down-regulated in TNBS-induced rat colitis.

Authors:  Guangxi Zhao; Jing Li; Jiyao Wang; Xizhong Shen; Jianyong Sun
Journal:  Biochem Biophys Res Commun       Date:  2013-11-25       Impact factor: 3.575

8.  Cloning of a water channel homolog expressed in brain meningeal cells and kidney collecting duct that functions as a stilbene-sensitive glycerol transporter.

Authors:  T Ma; A Frigeri; H Hasegawa; A S Verkman
Journal:  J Biol Chem       Date:  1994-08-26       Impact factor: 5.157

9.  Interferon-γ suppresses intestinal epithelial aquaporin-1 expression via Janus kinase and STAT3 activation.

Authors:  Michael S Dicay; Christina L Hirota; Natalie J Ronaghan; Michael A Peplowski; Raza S Zaheer; Colin A Carati; Wallace K MacNaughton
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

10.  Tumor necrosis factor α decreases aquaporin 3 expression in intestinal epithelial cells through inhibition of constitutive transcription.

Authors:  Michael A Peplowski; Andrew J Vegso; Vadim Iablokov; Michael Dicay; Raza S Zaheer; Bernard Renaux; David Proud; Morley D Hollenberg; Paul L Beck; Wallace K MacNaughton
Journal:  Physiol Rep       Date:  2017-10-16
View more
  1 in total

1.  dDAVP Downregulates the AQP3-Mediated Glycerol Transport via V1aR in Human Colon HCT8 Cells.

Authors:  Mariangela Centrone; Mariagrazia D'Agostino; Marianna Ranieri; Maria Grazia Mola; Pinuccia Faviana; Piero Vincenzo Lippolis; Domenico Alessandro Silvestris; Maria Venneri; Annarita Di Mise; Giovanna Valenti; Grazia Tamma
Journal:  Front Cell Dev Biol       Date:  2022-07-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.